| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 33 | 2026 | 367 | 11.090 |
Why?
|
| Early Detection of Cancer | 36 | 2026 | 449 | 8.010 |
Why?
|
| Breast Neoplasms | 47 | 2026 | 1723 | 6.130 |
Why?
|
| Neoplasms | 26 | 2025 | 1377 | 4.700 |
Why?
|
| Health Knowledge, Attitudes, Practice | 20 | 2025 | 989 | 4.040 |
Why?
|
| Education, Nursing | 6 | 2023 | 20 | 3.850 |
Why?
|
| Mass Screening | 16 | 2025 | 541 | 3.190 |
Why?
|
| Egypt | 46 | 2025 | 54 | 3.130 |
Why?
|
| Middle Aged | 105 | 2026 | 12222 | 2.910 |
Why?
|
| Rural Population | 18 | 2026 | 373 | 2.820 |
Why?
|
| Humans | 165 | 2026 | 43102 | 2.670 |
Why?
|
| Female | 134 | 2026 | 24698 | 2.640 |
Why?
|
| Tanzania | 20 | 2026 | 28 | 2.560 |
Why?
|
| Urban Population | 16 | 2026 | 374 | 2.430 |
Why?
|
| Adult | 93 | 2026 | 13872 | 2.420 |
Why?
|
| Aged | 68 | 2026 | 8214 | 2.160 |
Why?
|
| Papillomavirus Infections | 9 | 2025 | 376 | 1.990 |
Why?
|
| Registries | 20 | 2026 | 437 | 1.970 |
Why?
|
| Delayed Diagnosis | 4 | 2026 | 38 | 1.920 |
Why?
|
| Patient Acceptance of Health Care | 13 | 2026 | 497 | 1.800 |
Why?
|
| Health Personnel | 4 | 2025 | 277 | 1.740 |
Why?
|
| Neoplasm Staging | 15 | 2026 | 374 | 1.710 |
Why?
|
| Poverty | 9 | 2026 | 400 | 1.690 |
Why?
|
| Incidence | 31 | 2026 | 1078 | 1.630 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2025 | 43 | 1.560 |
Why?
|
| Referral and Consultation | 4 | 2025 | 142 | 1.550 |
Why?
|
| Young Adult | 37 | 2026 | 5080 | 1.480 |
Why?
|
| Patient Education as Topic | 4 | 2019 | 235 | 1.370 |
Why?
|
| Mammography | 8 | 2025 | 212 | 1.350 |
Why?
|
| Colorectal Neoplasms | 7 | 2025 | 512 | 1.330 |
Why?
|
| Needs Assessment | 3 | 2019 | 178 | 1.300 |
Why?
|
| Mentors | 5 | 2021 | 145 | 1.190 |
Why?
|
| Artificial Intelligence | 3 | 2025 | 112 | 1.120 |
Why?
|
| Brain Neoplasms | 2 | 2025 | 140 | 1.110 |
Why?
|
| Education, Professional | 2 | 2019 | 9 | 1.090 |
Why?
|
| Morocco | 15 | 2025 | 16 | 1.050 |
Why?
|
| Papillomaviridae | 4 | 2025 | 142 | 1.040 |
Why?
|
| Students | 6 | 2021 | 626 | 0.990 |
Why?
|
| Adolescent | 31 | 2025 | 6081 | 0.970 |
Why?
|
| HIV Infections | 7 | 2025 | 2586 | 0.960 |
Why?
|
| Pancreatic Neoplasms | 7 | 2010 | 218 | 0.940 |
Why?
|
| Developing Countries | 7 | 2021 | 113 | 0.930 |
Why?
|
| Receptors, Estrogen | 7 | 2019 | 183 | 0.930 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2016 | 154 | 0.920 |
Why?
|
| Arabs | 4 | 2014 | 19 | 0.920 |
Why?
|
| Case-Control Studies | 19 | 2020 | 1285 | 0.890 |
Why?
|
| Papillomavirus Vaccines | 4 | 2021 | 174 | 0.880 |
Why?
|
| Specimen Handling | 1 | 2025 | 63 | 0.860 |
Why?
|
| Problem-Based Learning | 2 | 2021 | 42 | 0.850 |
Why?
|
| Medical Records | 4 | 2019 | 48 | 0.840 |
Why?
|
| Epidemiology | 2 | 2016 | 9 | 0.820 |
Why?
|
| Health Policy | 1 | 2025 | 184 | 0.810 |
Why?
|
| Education, Graduate | 2 | 2016 | 31 | 0.800 |
Why?
|
| Aged, 80 and over | 20 | 2026 | 2853 | 0.800 |
Why?
|
| Self Care | 1 | 2025 | 175 | 0.790 |
Why?
|
| Zambia | 5 | 2026 | 50 | 0.790 |
Why?
|
| Retrospective Studies | 16 | 2025 | 2544 | 0.780 |
Why?
|
| Biomedical Research | 3 | 2016 | 502 | 0.750 |
Why?
|
| Male | 44 | 2026 | 23409 | 0.730 |
Why?
|
| Universities | 3 | 2021 | 559 | 0.730 |
Why?
|
| Gelatin | 1 | 2022 | 17 | 0.720 |
Why?
|
| Eye Diseases | 1 | 2022 | 29 | 0.700 |
Why?
|
| Ovarian Neoplasms | 2 | 2016 | 415 | 0.690 |
Why?
|
| Hydrogels | 1 | 2022 | 59 | 0.690 |
Why?
|
| Multiple Myeloma | 1 | 2021 | 48 | 0.680 |
Why?
|
| Breast Neoplasms, Male | 4 | 2014 | 8 | 0.680 |
Why?
|
| Environmental Exposure | 7 | 2015 | 256 | 0.670 |
Why?
|
| Students, Medical | 2 | 2021 | 158 | 0.670 |
Why?
|
| Prostatic Neoplasms | 3 | 2024 | 1092 | 0.660 |
Why?
|
| Tunisia | 7 | 2022 | 7 | 0.660 |
Why?
|
| Colombia | 3 | 2025 | 31 | 0.660 |
Why?
|
| Age Distribution | 14 | 2025 | 249 | 0.650 |
Why?
|
| rho GTP-Binding Proteins | 3 | 2011 | 28 | 0.650 |
Why?
|
| Time Factors | 9 | 2025 | 1857 | 0.650 |
Why?
|
| Lymphatic Metastasis | 3 | 2024 | 81 | 0.640 |
Why?
|
| Biological Products | 1 | 2022 | 91 | 0.640 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2021 | 95 | 0.630 |
Why?
|
| Michigan | 11 | 2018 | 57 | 0.630 |
Why?
|
| Atherosclerosis | 1 | 2022 | 169 | 0.620 |
Why?
|
| Child | 18 | 2025 | 3443 | 0.610 |
Why?
|
| Insurance, Health | 4 | 2026 | 145 | 0.610 |
Why?
|
| Risk Factors | 23 | 2021 | 3994 | 0.600 |
Why?
|
| Hepatitis C, Chronic | 3 | 2015 | 44 | 0.590 |
Why?
|
| Adenocarcinoma | 5 | 2012 | 291 | 0.590 |
Why?
|
| Myocardial Infarction | 1 | 2022 | 247 | 0.590 |
Why?
|
| Neoplasms, Glandular and Epithelial | 2 | 2016 | 57 | 0.580 |
Why?
|
| Genes, ras | 3 | 2007 | 24 | 0.570 |
Why?
|
| Genes, p53 | 3 | 2007 | 27 | 0.570 |
Why?
|
| Vaginal Smears | 4 | 2013 | 63 | 0.570 |
Why?
|
| Uterine Neoplasms | 1 | 2019 | 53 | 0.560 |
Why?
|
| Stroke | 1 | 2022 | 340 | 0.540 |
Why?
|
| Medicine, African Traditional | 2 | 2014 | 8 | 0.540 |
Why?
|
| Minority Health | 3 | 2016 | 95 | 0.530 |
Why?
|
| Prognosis | 6 | 2021 | 861 | 0.510 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2011 | 186 | 0.500 |
Why?
|
| Health Education | 4 | 2023 | 363 | 0.490 |
Why?
|
| Minority Groups | 3 | 2021 | 690 | 0.490 |
Why?
|
| HIV Seropositivity | 2 | 2015 | 196 | 0.490 |
Why?
|
| Indians, North American | 3 | 2014 | 192 | 0.490 |
Why?
|
| Patient Compliance | 3 | 2019 | 233 | 0.480 |
Why?
|
| SEER Program | 10 | 2026 | 164 | 0.480 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2016 | 44 | 0.470 |
Why?
|
| Liver Cirrhosis | 2 | 2015 | 67 | 0.470 |
Why?
|
| Age Factors | 10 | 2021 | 1154 | 0.470 |
Why?
|
| Attitude to Health | 3 | 2014 | 338 | 0.460 |
Why?
|
| Socioeconomic Factors | 8 | 2025 | 1234 | 0.450 |
Why?
|
| United States | 17 | 2026 | 5205 | 0.450 |
Why?
|
| Models, Economic | 1 | 2014 | 28 | 0.440 |
Why?
|
| Islam | 1 | 2014 | 17 | 0.440 |
Why?
|
| Refugees | 1 | 2014 | 21 | 0.430 |
Why?
|
| Sarcoma, Kaposi | 1 | 2014 | 23 | 0.430 |
Why?
|
| Communication Barriers | 2 | 2012 | 60 | 0.430 |
Why?
|
| Internationality | 2 | 2021 | 37 | 0.430 |
Why?
|
| Infant | 8 | 2025 | 1175 | 0.430 |
Why?
|
| Cross-Sectional Studies | 10 | 2022 | 3156 | 0.420 |
Why?
|
| Educational Status | 5 | 2021 | 339 | 0.420 |
Why?
|
| Child, Preschool | 9 | 2025 | 1546 | 0.420 |
Why?
|
| Nebraska | 5 | 2020 | 5 | 0.400 |
Why?
|
| Mortality | 2 | 2025 | 175 | 0.400 |
Why?
|
| Mutation | 3 | 2007 | 1177 | 0.400 |
Why?
|
| Hepatitis C | 1 | 2014 | 139 | 0.400 |
Why?
|
| Logistic Models | 11 | 2021 | 1009 | 0.390 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 307 | 0.390 |
Why?
|
| Antiviral Agents | 1 | 2014 | 195 | 0.380 |
Why?
|
| Follow-Up Studies | 5 | 2016 | 1067 | 0.380 |
Why?
|
| DNA, Neoplasm | 3 | 2009 | 92 | 0.380 |
Why?
|
| Quality of Health Care | 1 | 2013 | 161 | 0.370 |
Why?
|
| Survival Rate | 5 | 2018 | 355 | 0.360 |
Why?
|
| Health Care Costs | 2 | 2026 | 91 | 0.360 |
Why?
|
| Reproducibility of Results | 5 | 2024 | 1081 | 0.360 |
Why?
|
| DNA Methylation | 3 | 2013 | 403 | 0.360 |
Why?
|
| Health Status Disparities | 2 | 2018 | 719 | 0.350 |
Why?
|
| Career Choice | 1 | 2011 | 52 | 0.340 |
Why?
|
| Molecular Epidemiology | 5 | 2011 | 59 | 0.320 |
Why?
|
| International Cooperation | 1 | 2010 | 52 | 0.320 |
Why?
|
| Education, Medical | 3 | 2012 | 118 | 0.310 |
Why?
|
| Smoking | 5 | 2015 | 1024 | 0.310 |
Why?
|
| Anti-HIV Agents | 1 | 2014 | 486 | 0.310 |
Why?
|
| Head and Neck Neoplasms | 1 | 2010 | 81 | 0.310 |
Why?
|
| Life Style | 4 | 2015 | 334 | 0.300 |
Why?
|
| Prevalence | 6 | 2026 | 1612 | 0.300 |
Why?
|
| Africa, Northern | 3 | 2020 | 6 | 0.300 |
Why?
|
| Romania | 2 | 2025 | 7 | 0.290 |
Why?
|
| Cost of Illness | 2 | 2026 | 98 | 0.270 |
Why?
|
| Age of Onset | 2 | 2025 | 114 | 0.270 |
Why?
|
| Multivariate Analysis | 4 | 2013 | 638 | 0.270 |
Why?
|
| Vesicular Transport Proteins | 1 | 2007 | 48 | 0.270 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2009 | 163 | 0.260 |
Why?
|
| Environmental Pollution | 1 | 2007 | 27 | 0.260 |
Why?
|
| Health Services Accessibility | 4 | 2025 | 706 | 0.260 |
Why?
|
| Cost-Benefit Analysis | 3 | 2018 | 179 | 0.260 |
Why?
|
| Inflammation | 3 | 2022 | 758 | 0.260 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 224 | 0.250 |
Why?
|
| Environmental Pollutants | 4 | 2013 | 201 | 0.250 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2026 | 11 | 0.240 |
Why?
|
| False Positive Reactions | 1 | 2025 | 28 | 0.240 |
Why?
|
| Occupations | 2 | 2019 | 27 | 0.230 |
Why?
|
| Microbiological Techniques | 1 | 2025 | 14 | 0.230 |
Why?
|
| Occupational Exposure | 3 | 2019 | 91 | 0.230 |
Why?
|
| Nuclear Proteins | 2 | 2006 | 333 | 0.220 |
Why?
|
| Treatment Outcome | 4 | 2019 | 1604 | 0.220 |
Why?
|
| Insurance Benefits | 1 | 2024 | 3 | 0.220 |
Why?
|
| Disease Progression | 2 | 2020 | 667 | 0.220 |
Why?
|
| Tuberculosis | 1 | 2025 | 78 | 0.220 |
Why?
|
| Quality of Life | 3 | 2014 | 616 | 0.220 |
Why?
|
| Lactation | 2 | 2010 | 44 | 0.220 |
Why?
|
| Pathology | 1 | 2024 | 8 | 0.220 |
Why?
|
| Cell Cycle Proteins | 1 | 2006 | 241 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 290 | 0.210 |
Why?
|
| Diagnostic Imaging | 1 | 2024 | 53 | 0.210 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2022 | 53 | 0.200 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2003 | 21 | 0.200 |
Why?
|
| Cervix Uteri | 1 | 2023 | 48 | 0.200 |
Why?
|
| Medicare | 1 | 2026 | 332 | 0.200 |
Why?
|
| Biopsy | 1 | 2023 | 177 | 0.190 |
Why?
|
| Computers | 1 | 2022 | 35 | 0.190 |
Why?
|
| Insecticides | 1 | 2003 | 54 | 0.190 |
Why?
|
| Severity of Illness Index | 1 | 2025 | 719 | 0.190 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2022 | 12 | 0.190 |
Why?
|
| Levonorgestrel | 1 | 2022 | 17 | 0.190 |
Why?
|
| Kenya | 1 | 2022 | 58 | 0.190 |
Why?
|
| Capacity Building | 1 | 2023 | 99 | 0.190 |
Why?
|
| Pregnancy | 3 | 2022 | 1772 | 0.190 |
Why?
|
| Immunoenzyme Techniques | 2 | 2016 | 114 | 0.190 |
Why?
|
| Ghana | 4 | 2014 | 36 | 0.180 |
Why?
|
| Program Evaluation | 2 | 2021 | 359 | 0.180 |
Why?
|
| Education, Pharmacy | 1 | 2003 | 57 | 0.180 |
Why?
|
| Excipients | 1 | 2022 | 25 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2017 | 734 | 0.180 |
Why?
|
| Polymerase Chain Reaction | 3 | 2014 | 455 | 0.180 |
Why?
|
| Carcinoma, Lobular | 3 | 2011 | 5 | 0.180 |
Why?
|
| DNA Damage | 1 | 2004 | 356 | 0.180 |
Why?
|
| Oman | 1 | 2021 | 7 | 0.180 |
Why?
|
| Phenols | 2 | 2013 | 107 | 0.180 |
Why?
|
| Colonic Neoplasms | 2 | 2015 | 223 | 0.180 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2011 | 31 | 0.170 |
Why?
|
| Ethiopia | 1 | 2021 | 16 | 0.170 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2021 | 32 | 0.170 |
Why?
|
| Prospective Studies | 2 | 2016 | 1600 | 0.170 |
Why?
|
| Focus Groups | 2 | 2014 | 423 | 0.170 |
Why?
|
| Mammals | 1 | 2022 | 112 | 0.170 |
Why?
|
| Fishes | 1 | 2022 | 73 | 0.170 |
Why?
|
| Swine | 1 | 2022 | 212 | 0.170 |
Why?
|
| Acetic Acid | 1 | 2021 | 19 | 0.170 |
Why?
|
| Medical Oncology | 1 | 2021 | 50 | 0.170 |
Why?
|
| Wound Healing | 1 | 2022 | 88 | 0.170 |
Why?
|
| Collagen | 1 | 2022 | 181 | 0.170 |
Why?
|
| Faculty | 1 | 2021 | 105 | 0.160 |
Why?
|
| Inflammation Mediators | 1 | 2022 | 140 | 0.160 |
Why?
|
| Cattle | 1 | 2022 | 498 | 0.160 |
Why?
|
| Odds Ratio | 4 | 2019 | 587 | 0.160 |
Why?
|
| Medically Underserved Area | 1 | 2021 | 120 | 0.160 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2014 | 89 | 0.160 |
Why?
|
| Receptors, Androgen | 2 | 2011 | 144 | 0.160 |
Why?
|
| Interviews as Topic | 3 | 2025 | 452 | 0.160 |
Why?
|
| Learning | 1 | 2021 | 161 | 0.160 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2011 | 25 | 0.160 |
Why?
|
| Waist Circumference | 1 | 2020 | 90 | 0.150 |
Why?
|
| Population Surveillance | 3 | 2018 | 246 | 0.150 |
Why?
|
| Industry | 1 | 2019 | 31 | 0.150 |
Why?
|
| Schools, Medical | 1 | 2021 | 208 | 0.150 |
Why?
|
| Vaccination | 1 | 2021 | 355 | 0.150 |
Why?
|
| Occupational Diseases | 1 | 2019 | 53 | 0.150 |
Why?
|
| Patient Readmission | 1 | 2021 | 122 | 0.150 |
Why?
|
| Travel | 1 | 2019 | 36 | 0.150 |
Why?
|
| Agriculture | 3 | 2019 | 66 | 0.150 |
Why?
|
| Nutrition Assessment | 1 | 2019 | 80 | 0.150 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2009 | 24 | 0.150 |
Why?
|
| Perception | 2 | 2021 | 215 | 0.150 |
Why?
|
| Infant, Newborn | 4 | 2010 | 972 | 0.140 |
Why?
|
| Adiposity | 1 | 2020 | 157 | 0.140 |
Why?
|
| Preventive Health Services | 1 | 2019 | 66 | 0.140 |
Why?
|
| Hepatitis B, Chronic | 2 | 2009 | 16 | 0.140 |
Why?
|
| Curriculum | 1 | 2021 | 318 | 0.140 |
Why?
|
| Cost Savings | 1 | 2018 | 18 | 0.140 |
Why?
|
| Mental Disorders | 1 | 2022 | 392 | 0.140 |
Why?
|
| Healthcare Disparities | 2 | 2015 | 590 | 0.140 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 148 | 0.140 |
Why?
|
| Oxidative Stress | 1 | 2004 | 1003 | 0.140 |
Why?
|
| Hospitals | 1 | 2019 | 117 | 0.140 |
Why?
|
| Premenopause | 3 | 2020 | 110 | 0.140 |
Why?
|
| Hair Removal | 1 | 2017 | 1 | 0.140 |
Why?
|
| Vulvar Neoplasms | 1 | 2017 | 10 | 0.130 |
Why?
|
| Body Mass Index | 2 | 2020 | 925 | 0.130 |
Why?
|
| Databases, Factual | 2 | 2015 | 341 | 0.130 |
Why?
|
| Burkina Faso | 1 | 2016 | 1 | 0.130 |
Why?
|
| Family | 2 | 2017 | 195 | 0.130 |
Why?
|
| Mexican Americans | 1 | 2019 | 226 | 0.130 |
Why?
|
| Mothers | 1 | 2019 | 215 | 0.130 |
Why?
|
| Breast Diseases | 1 | 2016 | 5 | 0.120 |
Why?
|
| Social Class | 3 | 2013 | 291 | 0.120 |
Why?
|
| Aging | 1 | 2022 | 783 | 0.120 |
Why?
|
| Health Resources | 2 | 2013 | 37 | 0.120 |
Why?
|
| Animals | 3 | 2023 | 16992 | 0.120 |
Why?
|
| Carboplatin | 1 | 2016 | 20 | 0.120 |
Why?
|
| Data Collection | 2 | 2013 | 210 | 0.120 |
Why?
|
| Benzhydryl Compounds | 2 | 2013 | 50 | 0.120 |
Why?
|
| HIV Seronegativity | 1 | 2015 | 41 | 0.120 |
Why?
|
| BRCA2 Protein | 2 | 2017 | 50 | 0.110 |
Why?
|
| Uridine Monophosphate | 1 | 2014 | 1 | 0.110 |
Why?
|
| Decision Trees | 1 | 2014 | 22 | 0.110 |
Why?
|
| Bhutan | 1 | 2014 | 1 | 0.110 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 518 | 0.110 |
Why?
|
| Ribavirin | 1 | 2014 | 21 | 0.110 |
Why?
|
| Laparoscopy | 1 | 2015 | 59 | 0.110 |
Why?
|
| Markov Chains | 1 | 2014 | 43 | 0.110 |
Why?
|
| Health Behavior | 2 | 2023 | 575 | 0.110 |
Why?
|
| Interferons | 1 | 2014 | 40 | 0.110 |
Why?
|
| National Health Programs | 1 | 2014 | 20 | 0.110 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2012 | 24 | 0.110 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2014 | 44 | 0.110 |
Why?
|
| Self Efficacy | 1 | 2015 | 215 | 0.110 |
Why?
|
| Sex Factors | 2 | 2015 | 1028 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 234 | 0.110 |
Why?
|
| Insurance Coverage | 1 | 2014 | 110 | 0.100 |
Why?
|
| Radio | 1 | 2013 | 2 | 0.100 |
Why?
|
| Poisson Distribution | 2 | 2010 | 44 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2015 | 263 | 0.100 |
Why?
|
| South Dakota | 1 | 2013 | 4 | 0.100 |
Why?
|
| North Dakota | 1 | 2013 | 2 | 0.100 |
Why?
|
| Iowa | 1 | 2013 | 10 | 0.100 |
Why?
|
| Early Diagnosis | 2 | 2011 | 68 | 0.100 |
Why?
|
| Consumer Health Information | 1 | 2013 | 24 | 0.100 |
Why?
|
| Air Pollutants | 1 | 2015 | 130 | 0.100 |
Why?
|
| India | 2 | 2010 | 108 | 0.100 |
Why?
|
| Polymorphism, Genetic | 2 | 2011 | 201 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 458 | 0.100 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2014 | 229 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2014 | 368 | 0.100 |
Why?
|
| Ultrasonography, Mammary | 1 | 2012 | 8 | 0.100 |
Why?
|
| Transients and Migrants | 1 | 2013 | 42 | 0.090 |
Why?
|
| Exercise | 1 | 2018 | 692 | 0.090 |
Why?
|
| Regression Analysis | 2 | 2010 | 490 | 0.090 |
Why?
|
| Rectal Neoplasms | 1 | 2012 | 20 | 0.090 |
Why?
|
| Latin America | 1 | 2012 | 55 | 0.090 |
Why?
|
| Parity | 2 | 2010 | 59 | 0.090 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2012 | 20 | 0.090 |
Why?
|
| Caribbean Region | 1 | 2012 | 79 | 0.090 |
Why?
|
| Menopause | 2 | 2009 | 64 | 0.090 |
Why?
|
| Telephone | 1 | 2012 | 36 | 0.090 |
Why?
|
| Peru | 1 | 2011 | 41 | 0.090 |
Why?
|
| Women's Health Services | 1 | 2011 | 12 | 0.090 |
Why?
|
| Colonic Polyps | 1 | 2012 | 71 | 0.090 |
Why?
|
| Geography | 1 | 2011 | 110 | 0.090 |
Why?
|
| Women's Health | 2 | 2025 | 160 | 0.090 |
Why?
|
| Breast Self-Examination | 1 | 2011 | 13 | 0.090 |
Why?
|
| Phthalic Acids | 1 | 2011 | 18 | 0.090 |
Why?
|
| Attitude | 1 | 2012 | 108 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 173 | 0.090 |
Why?
|
| Carcinoma, Papillary | 1 | 2011 | 15 | 0.080 |
Why?
|
| Acculturation | 1 | 2013 | 205 | 0.080 |
Why?
|
| Schistosomiasis | 2 | 2009 | 19 | 0.080 |
Why?
|
| Culture | 1 | 2012 | 172 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 223 | 0.080 |
Why?
|
| Risk Assessment | 4 | 2020 | 863 | 0.080 |
Why?
|
| Middle East | 1 | 2010 | 21 | 0.080 |
Why?
|
| Tobacco, Smokeless | 1 | 2010 | 19 | 0.080 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2010 | 25 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2010 | 27 | 0.080 |
Why?
|
| Oral Hygiene | 1 | 2010 | 23 | 0.080 |
Why?
|
| Asia | 1 | 2010 | 98 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 291 | 0.080 |
Why?
|
| Income | 2 | 2021 | 160 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2010 | 81 | 0.080 |
Why?
|
| Developed Countries | 1 | 2009 | 16 | 0.080 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2009 | 19 | 0.080 |
Why?
|
| Estradiol Congeners | 1 | 2009 | 2 | 0.070 |
Why?
|
| Feasibility Studies | 1 | 2010 | 259 | 0.070 |
Why?
|
| Carcinoma | 1 | 2010 | 108 | 0.070 |
Why?
|
| Gene Silencing | 1 | 2009 | 154 | 0.070 |
Why?
|
| Pain | 1 | 2011 | 290 | 0.070 |
Why?
|
| Epidemiologic Studies | 1 | 2007 | 33 | 0.070 |
Why?
|
| Tissue Array Analysis | 1 | 2007 | 80 | 0.070 |
Why?
|
| Peptides | 1 | 2011 | 372 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 1019 | 0.070 |
Why?
|
| Qualitative Research | 2 | 2025 | 574 | 0.060 |
Why?
|
| Research Design | 1 | 2009 | 385 | 0.060 |
Why?
|
| Androgens | 1 | 2007 | 106 | 0.060 |
Why?
|
| Exons | 1 | 2006 | 92 | 0.060 |
Why?
|
| Receptors, Progesterone | 3 | 2012 | 92 | 0.060 |
Why?
|
| Knowledge | 1 | 2006 | 16 | 0.060 |
Why?
|
| Education, Medical, Continuing | 1 | 2006 | 35 | 0.060 |
Why?
|
| Chi-Square Distribution | 3 | 2011 | 236 | 0.060 |
Why?
|
| Reproductive History | 2 | 2020 | 27 | 0.060 |
Why?
|
| Cadmium | 1 | 2006 | 56 | 0.060 |
Why?
|
| Health Promotion | 1 | 2012 | 704 | 0.060 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2006 | 67 | 0.060 |
Why?
|
| Models, Biological | 1 | 2009 | 712 | 0.060 |
Why?
|
| Smoking Cessation | 1 | 2012 | 590 | 0.060 |
Why?
|
| Workflow | 1 | 2025 | 26 | 0.060 |
Why?
|
| Particulate Matter | 1 | 2025 | 83 | 0.060 |
Why?
|
| Natural Language Processing | 1 | 2024 | 21 | 0.050 |
Why?
|
| Liver | 1 | 2007 | 511 | 0.050 |
Why?
|
| Activins | 1 | 2023 | 8 | 0.050 |
Why?
|
| Cachexia | 1 | 2023 | 7 | 0.050 |
Why?
|
| Arginase | 1 | 2023 | 15 | 0.050 |
Why?
|
| Physicians | 1 | 2006 | 188 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2015 | 224 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2004 | 124 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2009 | 968 | 0.050 |
Why?
|
| Estrogens | 1 | 2004 | 203 | 0.050 |
Why?
|
| Students, Dental | 1 | 2022 | 7 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2023 | 165 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 611 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2014 | 1759 | 0.050 |
Why?
|
| Primary Health Care | 1 | 2006 | 380 | 0.050 |
Why?
|
| Linear Models | 1 | 2003 | 317 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2004 | 465 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2021 | 52 | 0.040 |
Why?
|
| Argentina | 1 | 2021 | 14 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 384 | 0.040 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2021 | 10 | 0.040 |
Why?
|
| Myocardium | 1 | 2023 | 263 | 0.040 |
Why?
|
| Suicide | 1 | 2022 | 140 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2021 | 76 | 0.040 |
Why?
|
| Occult Blood | 1 | 2020 | 32 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2023 | 316 | 0.040 |
Why?
|
| Midwestern United States | 1 | 2019 | 21 | 0.040 |
Why?
|
| Government Programs | 1 | 2019 | 29 | 0.040 |
Why?
|
| Postmenopause | 1 | 2020 | 141 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2019 | 83 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2012 | 760 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2019 | 121 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2019 | 122 | 0.040 |
Why?
|
| Comorbidity | 1 | 2021 | 737 | 0.030 |
Why?
|
| Mexico | 1 | 2019 | 298 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2018 | 138 | 0.030 |
Why?
|
| Cause of Death | 1 | 2018 | 186 | 0.030 |
Why?
|
| Genitalia, Female | 1 | 2017 | 29 | 0.030 |
Why?
|
| Carcinoma, Medullary | 2 | 2008 | 3 | 0.030 |
Why?
|
| Bulgaria | 1 | 2016 | 1 | 0.030 |
Why?
|
| Europe, Eastern | 1 | 2016 | 3 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 2017 | 58 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2016 | 12 | 0.030 |
Why?
|
| Phenotype | 2 | 2011 | 780 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 94 | 0.030 |
Why?
|
| Professional Practice Location | 1 | 2015 | 17 | 0.030 |
Why?
|
| Depression | 1 | 2022 | 863 | 0.030 |
Why?
|
| Colectomy | 1 | 2015 | 24 | 0.030 |
Why?
|
| Cyprus | 1 | 2015 | 1 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 259 | 0.030 |
Why?
|
| Europe | 1 | 2015 | 115 | 0.030 |
Why?
|
| Anxiety | 1 | 2022 | 874 | 0.030 |
Why?
|
| Diet | 2 | 2011 | 826 | 0.030 |
Why?
|
| New Jersey | 1 | 2014 | 15 | 0.030 |
Why?
|
| Toxicogenetics | 1 | 2013 | 4 | 0.030 |
Why?
|
| Oncology Service, Hospital | 1 | 2013 | 3 | 0.020 |
Why?
|
| Cytosine | 1 | 2013 | 33 | 0.020 |
Why?
|
| Guanine | 1 | 2013 | 44 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2013 | 33 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2016 | 549 | 0.020 |
Why?
|
| Germany | 1 | 2012 | 26 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2013 | 207 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 238 | 0.020 |
Why?
|
| California | 1 | 2014 | 548 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 6644 | 0.020 |
Why?
|
| Program Development | 1 | 2013 | 240 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 152 | 0.020 |
Why?
|
| Cytodiagnosis | 1 | 2011 | 10 | 0.020 |
Why?
|
| Food Packaging | 1 | 2011 | 6 | 0.020 |
Why?
|
| Nigeria | 1 | 2011 | 92 | 0.020 |
Why?
|
| Human Development | 1 | 2011 | 9 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2011 | 30 | 0.020 |
Why?
|
| Trinucleotide Repeats | 1 | 2011 | 5 | 0.020 |
Why?
|
| Rural Health | 1 | 2011 | 55 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2015 | 469 | 0.020 |
Why?
|
| Urban Health | 1 | 2011 | 101 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 423 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2011 | 311 | 0.020 |
Why?
|
| Pesticides | 1 | 2010 | 62 | 0.020 |
Why?
|
| Religion | 1 | 2009 | 90 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 495 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 800 | 0.020 |
Why?
|
| Carcinoma in Situ | 1 | 2008 | 16 | 0.020 |
Why?
|
| Schistosomiasis haematobia | 1 | 2008 | 3 | 0.020 |
Why?
|
| Pancreatitis, Chronic | 1 | 2007 | 6 | 0.020 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2007 | 25 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2007 | 19 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2007 | 59 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 934 | 0.020 |
Why?
|
| Motor Activity | 1 | 2009 | 437 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2007 | 135 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2007 | 102 | 0.020 |
Why?
|
| Testosterone | 1 | 2007 | 211 | 0.020 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2005 | 5 | 0.020 |
Why?
|
| Genes, p16 | 1 | 2005 | 11 | 0.020 |
Why?
|
| Jordan | 1 | 2005 | 24 | 0.010 |
Why?
|
| Turkey | 1 | 2005 | 23 | 0.010 |
Why?
|
| Chromosomal Instability | 1 | 2005 | 20 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2005 | 61 | 0.010 |
Why?
|
| CpG Islands | 1 | 2005 | 109 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2007 | 258 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2005 | 206 | 0.010 |
Why?
|
| Educational Measurement | 1 | 2006 | 102 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 575 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2005 | 213 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2005 | 321 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2006 | 231 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2005 | 2157 | 0.010 |
Why?
|